Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quantum Biopharma ( (TSE:QNTM) ) just unveiled an announcement.
On September 10, 2025, Quantum BioPharma announced that Kingswood Capital Partners initiated analyst coverage on the company with a BUY rating and a US$45 price target. This assessment is based on the anticipated success of Phase 2 and 3 trials of Quantum’s lead compound, Lucid-MS, and its potential commercial launch in 2029. This coverage could positively impact Quantum BioPharma’s market positioning and investor confidence, as it highlights the company’s promising pipeline and strategic focus on innovative treatments for challenging disorders.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is actively involved in the research and development of its lead compound, Lucid-MS, which targets multiple sclerosis by preventing and reversing myelin degradation. Quantum BioPharma also holds a strategic investment portfolio and retains a significant ownership stake in Unbuzzd Wellness Inc., which markets an OTC product developed by Quantum.
Average Trading Volume: 6,062
Technical Sentiment Signal: Sell
Current Market Cap: C$68.69M
See more data about QNTM stock on TipRanks’ Stock Analysis page.